Published Paper Details:

Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by cognitive decline, memory loss, and behavioral changes. With over 50 million people worldwide affected by AD, early diagnosis and effective treatment strategies are essential for improving patient outcomes and reducing the burden on individuals, caregivers, and healthcare systems. Advancements in diagnostic techniques have significantly contributed to AD diagnosis. Neuroimaging techniques such as PET, MRI, fMRI, and amyloid imaging have emerged as valuable tools for detecting pathological changes associated with AD in the brain. Cerebrospinal fluid (CSF) biomarkers, including beta-amyloid peptides and tau proteins, have shown promise in early detection and differential diagnosis. Blood-based biomarkers such as plasma A? and tau levels, neurofilament light chain, and inflammatory markers are also being investigated for their diagnostic utility. Artificial intelligence (AI) and machine learning (ML) algorithms have demonstrated potential in enhancing the accuracy and efficiency of AD diagnosis by analyzing complex datasets. In terms of therapeutic advancements, significant progress has been made in developing disease-modifying therapies for AD. Approaches targeting beta-amyloid, tau protein, inflammation, and neuroprotection are being explored. Non-pharmacological interventions, including cognitive training, physical exercise, lifestyle modifications, and nutritional interventions, have shown promise in managing symptoms and improving quality of life for AD patients. Emerging therapeutic approaches, such as immunotherapy, gene therapy, stem cell therapy, and epigenetic modifications, are being investigated for their ability to target AD pathology and provide novel treatment options. Despite these advancements, challenges remain in AD diagnosis and treatment. Ethical considerations in early detection and predictive testing, ensuring access to innovative diagnostics and treatments, promoting precision medicine and personalized approaches, and fostering collaborative research efforts and clinical trials are crucial for further advancements in the field.